Below is Validea's guru fundamental report for ASML HOLDING NV (ADR) (ASML). Of the 22 guru strategies we follow, ASML rates highest using our Patient Investor model based on the published ...

Below is Validea's guru fundamental report for ASML HOLDING NV (ADR) (ASML). Of the 22 guru strategies we follow, ASML rates highest using our Patient Investor model based on the published ...

ROCKVILLE, MD, USA I March 19, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE ® trial of ...

RGX-202, a one-time gene therapy designed to treat Duchenne muscular dystrophy (DMD), has been well tolerated in an ongoing clinical trial, with no serious side effects reported. Interim data from the ...

US gene therapy company Regenxbio (Nasdaq: RGNX) has reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of RGX-202, an ...

RGX-202 shows the highest reported microdystrophin levels in ambulatory patients age 8+ among gene therapies. Regenxbio plans to submit a BLA for RGX-202 in mid-2026, with Phase 3 enrollment ...

For those with a long enough investing time horizon, ASML stock looks like a decent pick here. “The Next NVIDIA” Could Change Your Life NVIDIA has returned 250-fold in the past 10 years as ...

ASML (ASML) closed the latest trading day at $731.11, indicating a +0.11% change from the previous session's end. The stock's change was more than the S&P 500's daily loss of 1.07%. Elsewhere, the ...

Johan Thijs, CEO of KBC Group, is one of Europe’s most successful corporate leaders. Under his ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ASML’s current share buyback program was announced on 10 November 2022, and details are available on our website at https://www.asml.com/en/investors/why-invest-in ...